Skip to content
‹ Back to IndustriesSciences

How Science and Technology is Revolutionizing the Cannabis Industry

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies. Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques. According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development. “We’ve been able to…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Cannabis
Share

Key takeaways

01

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies.

02

Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques.

03

According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies. Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques.

According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development.

“We’ve been able to collect a significant more amount of data and learn from it, even just over the past five years,” said Peterson. “Besides that, the technology used to create a controlled environment inside in terms of lighting, fertigation, HVAC, have allowed us to also optimize plant growth and production and efficiency in these spaces.

In the same ways that farmers learn over time what crops grow best in what areas, we learn to isolate environmental factors to optimize plant growth. Starting with data collection, we better understand what the plants need.

These developments have decreased the number of days plants take to reach maturity and, in turn, increased the number of harvests a year within greenhouses. Specifically, within InSprire Transpiration Solutions, technology has increased harvest cycles from four per year to six. Similar techniques are developing in outdoor cannabis development and production.

In addition to environmental developments, we have also seen cannabis development in the plants themselves through crop steering and breeding. In the 1970s, THC levels in cannabis plants consistently registered 8-12%. Nowadays, plants are testing in the range of 35 to 40% with some cultivars. That’s a significant increase. A lot of that is down to the changes in plant breeding. However, targeted cultivation strategies also contribute to that shift.

Video TranscriptExpand ↓

Hi, my name is Anders Peterson with InSpire Transpiration Solutions. I'm an indoor cannabis cultivator for the past 12 years and a cell molecular biologist. And today, the question is how was an increased understanding of technology and science changing the cannabis industry? Well, a better understanding of science and technology has changed the cannabis industry in a number of ways. And specifically, when it comes to cultivation, it has allowed us to optimize plant performance, including yield and secondary metabolite concentration like cannabinoids and terpenes. And it's allowed us to optimize the production of the plant, primarily in an indoor setting, but also in the field. And in greenhouses. An example of this in an indoor scenario is that with data collection, a better understanding of the levers to pull for cultivation in terms of the Cardinal parameters of plant growth, we've been able to shorten cycle times and basically speed up plant growth so that we're getting additional harvests per year which is just increasing the bottom line for many of these cannabis cultivation businesses. For example, a while ago, an indoor flowering room would only get four harvest a year. Now we're shooting for getting six. So that's a significant more amount of product coming out of each space per year. All due to better understanding of science and technology. The advent of cheaper sensor technology and kind of the IOT of things has allowed us to learn a lot of these things that have, uh, you know, a lot of the parameters to optimize, because sensors have gotten so much cheaper more widely accessible. We've been able to collect a significant more amount of data and learn from it, even just over the past five years. Besides that, the technology used to create a controlled environment inside in terms of lighting, fertigation, HVAC, have allowed us to also optimize plant growth and production and efficiency in these spaces. So, really it's kind of changed the game, increasing, you know, a better understanding of technology and science. I'm looking forward to some really interesting research that's going to be coming out in the next year or so, that will even further optimize these indoor controlled environments, allowing us to reach new levels of plant performance in the cannabis crop that we've never seen before. I mean, just as a benchmark of back in the seventies, most cannabis dried flower tested in the THC percentages around eight to 12%. Nowadays, we're testing in the range of 35 to 40% with some cultivars. That's a significant increase. A lot of that is done through breeding, but also much more targeted cultivation strategy. That's allowed us to use techniques like crop steering, both in the irrigation side and in the environment that allow us to push the plant in certain predicted outcomes that are beneficial for the cultivator and for the crop. So it's really been quite amazing.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

The quantum cascade laser market is projected to grow 8% to 12% a year through 2035, driven by mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical quality checks. In these uses, the lasers offer high spectral brightness and run at room temperature in compact form factors. The installed base of analytical instruments is also growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan prefilled syringe plant in Shenzhen won the Innovation (Novel Technology) category at ISPE's 2026 Facility of the Year Awards. In the transcript ISPE posted with its podcast, CaiXue Wei describes vertical design, AGV-assisted transfer, AI inspection and 5G-MEC as one integrated system built around a 330 million-syringe annual capacity; Hepalink's own release adds a 24-meter warehouse, sub-10 millisecond 5G and 24,000-unit-an-hour inspection.

  • 01Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout on a land-scarce Shenzhen site supporting 330 million syringes a year.
  • 02AGVs pass material through vaporized hydrogen peroxide chambers straight into Grade A isolators, and Hepalink credits the zero-touch flow for a 100 percent first media fill.

Oct 22, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512